Advertisement
Articles
Advertisement

Focus on Outsourcing 5/5/06

Fri, 05/05/2006 - 5:28am
Gen-Probe Granted Rights to Tests for Prostate Cancer
The University of Michigan, Ann Arbor, licensed the exclusive worldwide rights to develop diagnostic tests for recently discovered genetic translocations shown to be highly specific for prostate cancer tissue to Gen-Probe Inc., San Diego.
Full Article

Acuity Licenses Anti-Inflammatory Agent from ZaBeCor
Acuity Pharmaceuticals, Philadelphia, entered into a license option agreement with ZaBeCor Pharmaceutical Co., Philadelphia, to develop and commercialize ophthalmic applications of a small interfering RNA agent to treat inflammatory disorders.
Full Article

FibroGen Grants Rights for Oral HIF-PH Inhibitors to Astellas
FibroGen Inc., South San Francisco, completed an exclusive licensing agreement with Astellas Pharma Inc., Tokyo, Japan, giving Astellas rights to certain FibroGen hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors to treat anemia.
Full Article

ImQuest Licenses Anti-Cancer Compounds from Samjin
ImQuest Pharmaceuticals Inc., Frederick, Md., signed an exclusive worldwide license for the development and commercialization rights to a novel piperazine series of anti-cancer agents discovered and patented by Samjin Pharmaceutical Co. Ltd., Seoul, Korea.
Full Article

XOMA to Use its Technology on AVEO Antibody
XOMA Ltd., Berkeley, Calif., will utilize its Human Engineering technology to humanize AV-299, a novel anti-HGF monoclonal antibody, from AVEO Pharmaceuticals Inc., Cambridge, Mass., which has demonstrated efficacy in preclinical models of human cancer.
Full Article

Ilypsa and Astellas Enter into Licensing Agreement
Ilypsa Inc., Santa Clara, Calif., and Astellas Pharma Inc., Tokyo, Japan, entered into a license agreement giving Astellas the exclusive rights to develop and market ILY101, a drug to treat hyperphosphatemia, which is abnormally high blood concentrations of phosphorus, in Japan.
Full Article

Elusys Grants Rights to Antibodies to MedImmune
Elusys Therapeutics Inc., Pine Brook, N.J., entered into an exclusive license and collaboration agreement with MedImmune Inc., Gaithersburg, Md., to develop therapeutics for infectious disease targets using Elusys' proprietary heteropolymer antibodies.
Full Article

Schwarz Grants License for Overactive Bladder Drug to Pfizer
Schwarz Pharma, Monheim, Germany, agreed to license fesoterodine, a bladder-control drug awaiting U.S. and European approval, to Pfizer Inc., New York, and to drop a patent lawsuit against Pfizer concerning the drug.
Full Article

Kissei Licenses Diabetes Drug to GSK
GlaxoSmithKline Plc (GSK), Brentford, UK, has licensed the exclusive rights from Kissei Pharmaceutical Co., Tokyo, Japan, to develop and market a diabetes drug that inhibits glucose absorption in the intestines, which is currently in a preclinical stage.
Full Article


Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading